Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment

Int J Nanomedicine. 2024 May 6:19:4021-4040. doi: 10.2147/IJN.S463679. eCollection 2024.

Abstract

Cataract is a leading cause of blindness globally, and its surgical treatment poses a significant burden on global healthcare. Pharmacologic therapies, including antioxidants and protein aggregation reversal agents, have attracted great attention in the treatment of cataracts in recent years. Due to the anatomical and physiological barriers of the eye, the effectiveness of traditional eye drops for delivering drugs topically to the lens is hindered. The advancements in nanomedicine present novel and promising strategies for addressing challenges in drug delivery to the lens, including the development of nanoparticle formulations that can improve drug penetration into the anterior segment and enable sustained release of medications. This review introduces various cutting-edge drug delivery systems for cataract treatment, highlighting their physicochemical properties and surface engineering for optimal design, thus providing impetus for further innovative research and potential clinical applications of anti-cataract drugs.

Keywords: cataract; drug delivery system; nanomedicine; ocular barrier.

Publication types

  • Review

MeSH terms

  • Animals
  • Cataract Extraction
  • Cataract* / drug therapy
  • Drug Delivery Systems* / methods
  • Humans
  • Lens, Crystalline / drug effects
  • Nanomedicine* / methods
  • Nanoparticle Drug Delivery System / chemistry
  • Nanoparticles / chemistry
  • Ophthalmic Solutions / administration & dosage
  • Ophthalmic Solutions / chemistry
  • Ophthalmic Solutions / pharmacokinetics

Substances

  • Nanoparticle Drug Delivery System
  • Ophthalmic Solutions

Grants and funding

This work was supported by National Natural Science Foundation of China (No.82070937; No.82101097; No.82271628).